International Center for Advancement of Addiction Treatment

The International Center for Advancement of Addiction Treatment "is generously supported by The Edmond de Rothschild Foundation, which shares the commitment to advance the quality of care for those suffering from chemical dependency."

" To provide individuals living with opioid addiction, and those committed to their well-being, reliable information concerning treatment options and prevailing policies and practices of treatment providers."

Contributors and Key Staff
Accessed October 2008:


 * Olof Blix, MD 	Medical Director, Methadone Clinic at the Bergen Clinics Foundation (Norway)
 * Naomi Braine 	Project Director, The Baron Edmond de Rothschild Chemical Dependency Institute (United States)
 * Veronica Catan 	Project Director, The Baron Edmond de Rothschild Chemical Dependency Institute (United States)
 * Holly Catania, JD 	Project Director, International Center for Advancement of Addiction Treatment
 * Barbara Cooper-Gordon 	Administrative Director, Stuyvesant Square Chemical Dependency Treatment Services (United States)
 * Anne Coppel, MD 	Director, Emergence Espace-Tolbiac, Paris (France)
 * Addie Corradi 	Administrative Director, Methadone Maintenance Treatment Program (United States)
 * Don C. Des Jarlais, PhD* 	Director, Research, The Baron Edmond de Rothschild Chemical Dependency Institute (United States)
 * Vincent Dole, MD 	Professor Emeritus, The Rockefeller University (United States)
 * Herbert Elias, MD 	General Medicine Physician, specializing in the treatment of patients with opiate addiction (Germany)
 * Paul H. Epstein, Esq* 	Partner, Proskauer Rose LLP, NYC; President, The Edmond de Rothschild Foundation (United States)
 * Loretta P. Finnegan, MD 	Medical Advisor to the Director, Office of Research on Women's Health (United States)
 * Mitchell A. Kaplan, PhD 	Research Project Manager, Institute for Education and Research in the Department of Pain Medicine and Palliative Care at Beth Israel Medical Center (United States)
 * Stanley Komaroff, Esq* 	Partner, Proskauer Rose LLP, NYC,Director, The Edmond de Rothschild Foundation (United States)
 * William Lowenstein, MD* 	Director, Center for Addiction Medicine, Centre Monte Cristo Laennec, Paris (France)
 * Courtney McKnight 	Project Director, The Baron Edmond de Rothschild Chemical Dependency Institute (United States)
 * Judith Milliken 	Administrative Coordinator, The Baron Edmond de Rothschild Chemical Dependency Institute (United States)
 * Ethan A. Nadelmann, PhD, JD* 	Executive Director, The Lindesmith Center-Drug Policy Foundation (United States)
 * Robert G. Newman, MD* 	Director, The Baron Edmond de Rothschild Chemical Dependency Institute (United States)
 * Russell K. Portenoy, MD* 	Chairman, Department of Pain Medicine and Palliative Care, Beth Israel Medical Center (United States)
 * Marc Reisinger, MD 	Vice-President, European Opiate Addiction Treatment Association (EUROPAD)
 * Beverly L. Richman, MD 	Chief, Medical Services, Methadone Maintenance Treatment Program (United States)
 * Howard J. Rosso, RN 	Director, Patient Care Services, Methadone Maintenance Treatment Program (United States)
 * Nadim Salomon, MD 	Medical Director, Peter Krueger Center for Immunological Disorders (United States)
 * Edwin A. Salsitz, MD 	Director, Methadone Medical Maintenance Program (United States)
 * Peter Vanderkloot 	Advocate for Patient Rights (United States)
 * Alex Wodak, MD 	Director of the Alcohol and Drug Service, St. Vincent's Hospital, Darlinghurst (Australia)
 * Stanley Yancovitz, MD 	Chief, Division of Chemical Dependency & Medical Director of Stuyvesant Square Chemical Dependency Treatment Services (United States)
 * Stuart C. Yudofsky, MD* 	Professor and Chairman, Department of Psychiatry and Behavioral Sciences Baylor College of Medicine, Houston, TX (United States)
 * Catherine Zadoretzky 	Research Associate, The Baron Edmond de Rothschild Chemical Dependency Institute (United States)

Contact

 * Web: http://www.drugaddictionrx.com